MX2017003694A - Sistema de genética inversa del virus pichindé y métodos de uso. - Google Patents
Sistema de genética inversa del virus pichindé y métodos de uso.Info
- Publication number
- MX2017003694A MX2017003694A MX2017003694A MX2017003694A MX2017003694A MX 2017003694 A MX2017003694 A MX 2017003694A MX 2017003694 A MX2017003694 A MX 2017003694A MX 2017003694 A MX2017003694 A MX 2017003694A MX 2017003694 A MX2017003694 A MX 2017003694A
- Authority
- MX
- Mexico
- Prior art keywords
- coding region
- methods
- reverse genetics
- genetics system
- region encoding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En la presente se proporcionan virus Pichindé modificados genéticamente que incluyen tres segmentos genómicos ambisentido. El primer segmento genómico incluye una región codificante que codifica una proteína Z y una región codificante que codifica una proteína RdRp L. El segundo segmento genómico incluye una región codificante que codifica una nucleoproteína (NP) y el tercer segmento genómico incluye una región codificante que codifica una glicoproteína. Cada uno del segundo y tercer segmento genómico incluye opcionalmente una región codificante adicional que puede codificar un antígeno o un marcador detectable. En la presente también se proporciona un sistema de genética inversa para elaborar un virus Pichindé modificado genéticamente, y una recopilación de vectores que se puede usar para producir un virus Pichindé modificado genéticamente. También se proporcionan métodos para usar un sistema de genética inversa, así como métodos para producir una respuesta inmunitaria en un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053443P | 2014-09-22 | 2014-09-22 | |
| PCT/US2015/051337 WO2016048949A1 (en) | 2014-09-22 | 2015-09-22 | Pichinde virus reverse genetics system and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003694A true MX2017003694A (es) | 2017-10-12 |
Family
ID=54238628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003694A MX2017003694A (es) | 2014-09-22 | 2015-09-22 | Sistema de genética inversa del virus pichindé y métodos de uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10533159B2 (es) |
| EP (1) | EP3198008B1 (es) |
| JP (1) | JP6875274B6 (es) |
| KR (1) | KR20170057384A (es) |
| CN (1) | CN107109371A (es) |
| AU (1) | AU2015321557B2 (es) |
| BR (1) | BR112017005744B1 (es) |
| CA (1) | CA2961913A1 (es) |
| ES (1) | ES2746150T3 (es) |
| MX (1) | MX2017003694A (es) |
| PL (1) | PL3198008T3 (es) |
| WO (1) | WO2016048949A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2746150T3 (es) | 2014-09-22 | 2020-03-04 | Univ Minnesota | Sistema de genética inversa para el virus Pichindé y métodos de uso |
| WO2016075250A1 (en) * | 2014-11-13 | 2016-05-19 | Université De Genève | Tri-segmented arenaviruses as vaccine vectors |
| WO2016198531A2 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| BR112018009032A8 (pt) | 2015-11-04 | 2019-02-26 | Hookipa Biotech Ag | vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração |
| DK3373959T3 (da) | 2015-11-12 | 2022-09-19 | Hookipa Biotech Gmbh | Arenaviruspartikler som cancervacciner |
| CN109804074B (zh) | 2016-05-18 | 2023-10-10 | 巴塞尔大学 | 作为疫苗载体的三区段pichinde病毒 |
| BR112023002156A2 (pt) * | 2020-08-06 | 2023-05-02 | Univ Minnesota | Vacinas multivalentes contra reovírus da artrite de peru |
| WO2022269362A2 (en) | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
| CN101801189B (zh) * | 2007-08-27 | 2015-08-26 | 基内塔第四有限责任公司 | 用于治疗沙粒病毒感染的抗病毒药 |
| AP3126A (en) | 2007-12-21 | 2015-02-28 | Government Of The Us Secretary | Recombinant rift valley fever (RVF) viruses and methods of use |
| LT2604695T (lt) * | 2007-12-27 | 2022-12-12 | Universität Zürich | Replikacijos defektų turintys arenaviruso vektoriai |
| US20120219576A1 (en) | 2009-09-16 | 2012-08-30 | The Administrators Of The Tulane Educational Fund | Lassa virus-like particles and methods of production thereof |
| GB201007790D0 (en) | 2010-05-10 | 2010-06-23 | Isis Innovation | Compositions |
| US20130209406A1 (en) | 2010-06-06 | 2013-08-15 | Benjamin R. tenOever | Recombinant rna viruses and uses thereof |
| ES2746150T3 (es) | 2014-09-22 | 2020-03-04 | Univ Minnesota | Sistema de genética inversa para el virus Pichindé y métodos de uso |
-
2015
- 2015-09-22 ES ES15772173T patent/ES2746150T3/es active Active
- 2015-09-22 BR BR112017005744-1A patent/BR112017005744B1/pt active IP Right Grant
- 2015-09-22 CN CN201580063072.3A patent/CN107109371A/zh active Pending
- 2015-09-22 CA CA2961913A patent/CA2961913A1/en active Pending
- 2015-09-22 AU AU2015321557A patent/AU2015321557B2/en active Active
- 2015-09-22 JP JP2017515764A patent/JP6875274B6/ja active Active
- 2015-09-22 PL PL15772173T patent/PL3198008T3/pl unknown
- 2015-09-22 WO PCT/US2015/051337 patent/WO2016048949A1/en active Application Filing
- 2015-09-22 MX MX2017003694A patent/MX2017003694A/es unknown
- 2015-09-22 EP EP15772173.9A patent/EP3198008B1/en active Active
- 2015-09-22 US US15/513,045 patent/US10533159B2/en active Active
- 2015-09-22 KR KR1020177010589A patent/KR20170057384A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015321557B2 (en) | 2020-05-14 |
| ES2746150T3 (es) | 2020-03-04 |
| EP3198008B1 (en) | 2019-05-29 |
| JP6875274B6 (ja) | 2021-06-30 |
| CA2961913A1 (en) | 2016-03-31 |
| CN107109371A (zh) | 2017-08-29 |
| WO2016048949A1 (en) | 2016-03-31 |
| KR20170057384A (ko) | 2017-05-24 |
| BR112017005744A2 (pt) | 2017-12-12 |
| JP2017529084A (ja) | 2017-10-05 |
| US20170292119A1 (en) | 2017-10-12 |
| US20200165578A1 (en) | 2020-05-28 |
| US10533159B2 (en) | 2020-01-14 |
| AU2015321557A1 (en) | 2017-04-06 |
| BR112017005744B1 (pt) | 2023-11-28 |
| EP3198008A1 (en) | 2017-08-02 |
| PL3198008T3 (pl) | 2020-03-31 |
| JP6875274B2 (ja) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017003694A (es) | Sistema de genética inversa del virus pichindé y métodos de uso. | |
| CY1122705T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας,και μεθοδοι χρησης τους | |
| CY1124845T1 (el) | Μεθοδοι παροχης μονοκλωνου rna | |
| PH12019501227A1 (en) | Synthetic immune receptors and methods of use thereof | |
| MX2018008413A (es) | Virus oncolitico modificado. | |
| CY1122701T1 (el) | Απελευθερωση πρωτεϊνης με βαση βακτηρια | |
| CY1120740T1 (el) | Βελτιωμενα ευλογοϊικα εμβολια | |
| MX2016009746A (es) | Acelerador de cemento pasivado. | |
| CY1119093T1 (el) | Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο | |
| SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
| SG10201807208RA (en) | Viral resistant cells and uses thereof | |
| PH12016501705A1 (en) | Immunostimulatory plasmids | |
| SG10201903349YA (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| NZ761537A (en) | Anti-human ox40l antibodies, uses & methods | |
| MX2017007196A (es) | Fibroblastos de embrion de pollo inmortalizados. | |
| MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
| TR201900124T4 (tr) | Dispersiyon Reçineleri | |
| EA201590829A1 (ru) | Новые мукозные адъюванты и системы доставки | |
| MX2016013631A (es) | Celulas huespedes modificadas y usos de las mismas. | |
| MX369776B (es) | Vectores recombinantes del virus isfahan. | |
| PH12016501689B1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| WO2018067582A3 (en) | Hiv-1 env fusion peptide immunogens and their use | |
| MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
| BR112015014195A2 (pt) | método | |
| PH12017500539A1 (en) | Authentication system and method |